Adipotide
Also known as FTTP, Prohibitin-targeting peptide
An experimental peptidomimetic studied preclinically for targeting adipose vasculature through prohibitin-related mechanisms, with major translational and safety uncertainty.
Overview
Adipotide, also called FTTP, is an experimental compound designed to target blood vessels supplying white adipose tissue. It is not a standard metabolic peptide like GLP-1 drugs.
The Science
The research concept is vascular targeting: interfere with adipose tissue support structures rather than directly modulating appetite hormones.
- Adipose vasculature - proposed targeting of blood supply to fat tissue.
- Prohibitin-related binding - often described as part of the targeting logic.
- Preclinical obesity models - much of the attention comes from animal research.
Evidence Snapshot
Adipotide remains a high-uncertainty research compound. The mechanism is aggressive compared with nutrient or incretin approaches, so safety and translation questions are central.
Related
More in Metabolic
AICAR
Research compoundMetabolic
Not a peptideNucleotide analog
A nucleotide analog and AMPK-pathway research tool studied in cellular energy sensing, exercise-mimetic biology, cardiometabolic research, and anti-doping contexts.
AOD-9604
Research compoundMetabolic
A synthetic fragment of growth hormone designed to isolate GH's fat-mobilizing effects without its growth-promoting or blood-sugar-altering activity — a tool researchers and self-experimenters study for body composition and joint health.
Cagrilintide
InvestigationalMetabolic
An investigational long-acting amylin analog studied for appetite regulation, satiety, obesity, and combination use with semaglutide in CagriSema.